Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | BTK and BCL-2 inhibitor combination therapies in CLL

Nitin Jain • 17 Sep 2020
SOHO 2020
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Venetoclax
CAPTIVATE

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the combination use of BTK inhibitors (ibrutinib and acalabrutinib) and the BCL-2 inhibitor, venetoclax, in patients with chronic lymphocytic leukemia (CLL), and clinical studies evaluating their use, including the Phase II CAPTIVATE trial (NCT02910583). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nitin Jain

1:13
5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax
Nitin Jain • 10 Dec 2023
1:06
An ongoing Phase I trial evaluating AS-1763, a novel non-covalent BTKi, in B-cell lymphomas
Nitin Jain • 10 Dec 2023
1:43
Long-term outcomes of the iFCG regimen for firstline treatment of patients with IGHV-mutated CLL
Nitin Jain • 10 Dec 2023
1:54
Nivolumab + ibrutinib for patients with Richter’s transformation
Nitin Jain • 7 Sep 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals